NovaBridge Biosciences (NASDAQ:NBP) ("NovaBridge" or the "Company"), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Company's Board of Directors, effective July 1, 2026. Xi-Yong (Sean) Fu, PhD MBA will step down as Chief Executive Officer to pursue other opportunities. Dr. Fu will support the Company in an advisory capacity during the transition.

Dr. Gupta is an experienced CEO who brings more than two decades of transformative leadership across biopharmaceuticals, global health, and strategy. As CEO of NovaBridge, she will focus on advancing givastomig toward registration, expanding the ophthalmology franchise under Visara, and establishing strategic partnerships to maximize the potential of the Company’s medicines for patients and shareholders globally.

"Srishti’s perspective as both a physician and CEO makes her uniquely suited to lead NovaBridge," said Fu Wei, Chairman of the Board of NovaBridge. "Her global commercial experience and proven ability to build strategic partnerships positions NovaBridge to advance givastomig and VIS-101 toward registration, and deliver innovative medicines to patients. I am confident in her ability to create lasting value for our patients and shareholders. The Board and I are grateful to Sean Fu for his contributions to NovaBridge as our former CEO and wish him well in his future endeavors."

"Extraordinary science is being created faster than the industry's ability to bring it to patients — and NovaBridge was built to bridge that gap," said Dr. Gupta. "We believe our competitive advantage is identifying underappreciated, differentiated assets and advancing them toward registration and global reach through the right partnerships. My immediate priority is delivering on that promise for patients and shareholders."